Compounds > lazabemide
Page last updated: 2024-08-25

lazabemide and selegiline

lazabemide has been researched along with selegiline in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.57)18.7374
1990's9 (32.14)18.2507
2000's5 (17.86)29.6817
2010's12 (42.86)24.3611
2020's1 (3.57)2.80

Authors

AuthorsStudies
Bernard, S; Burstein, C; Curet, O; Gueddari, S; Lebreton, L; Mazouz, F; Milcent, R1
Toprakçí, M; Yelekçi, K1
Bergh, JJ; Mentz, W; Mostert, S; Petzer, A; Petzer, JP1
Bergh, JJ; Petzer, JP; Strydom, B1
Meiring, L; Petzer, A; Petzer, JP1
Legoabe, LJ; Petzer, A; Petzer, JP1
Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R1
Engelbrecht, I; Petzer, A; Petzer, JP1
Lourens, AC; Minders, C; Petzer, A; Petzer, JP1
Mostert, S; Petzer, A; Petzer, JP2
Legoabe, LJ; Petzer, A; Petzer, JP; Qhobosheane, MA1
Efimova, J; Ivanovskii, S; Petzer, A; Petzer, JP; Shetnev, A; Shlenev, R; Tarasov, A1
Dedecengiz, E; Erikci, A; Gokhan-Kelekci, N; Kaynak, FB; Salgin-Goksen, U; Tel, BC; Telli, G; Ucar, G; Yelekci, K1
Bench, CJ; Cremer, JE; Frackowiak, RS; Lammertsma, AA; Luthra, SK; Price, GW; Turton, D; Wood, ND1
Bench, CJ; Cremer, JC; Da Prada, M; Dingemanse, J; Dolan, RJ; Kettler, R; Lammertsma, AA; Luthra, SK; Price, GW; Turton, D1
Ogawa, N1
Da Prada, M; Haefely, WE; Keller, HH; Kettler, R1
Cesura, AM; Da Prada, M; Kettler, R; Richards, JG1
Bondiolotti, GP; Galva, MD; Picotti, GB; Sciaba, L; Villa, F1
Abercrombie, ED; Wachtel, SR1
LeWitt, PA; Mistura, KL; Schork, MA; Segel, SA1
Alexoff, D; Fowler, JS; Logan, J; MacGregor, RR; Pappas, N; Schlyer, DJ; Shea, C; Volkow, ND; Wang, GJ; Wolf, AP1
Jacob, RF; Mason, RP; Olmstead, EG1
Haapalinna, A; Jolkkonen, J; Kauppinen, R; Nyman, L; Sivenius, J1
LeWitt, PA1
Counsell, CE; Ives, N; Macleod, AD; Stowe, R1
Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C1

Reviews

4 review(s) available for lazabemide and selegiline

ArticleYear
[New anti-parkinsonian drugs].
    No to shinkei = Brain and nerve, 1991, Volume: 43, Issue:8

    Topics: Antiparkinson Agents; Bromocriptine; Humans; Lisuride; Parkinson Disease; Pergolide; Picolinic Acids; Selegiline

1991
Clinical trials of neuroprotection for Parkinson's disease.
    Neurology, 2004, Oct-12, Volume: 63, Issue:7 Suppl 2

    Topics: Antiparkinson Agents; Clinical Trials as Topic; Creatine; Dopamine Agonists; Double-Blind Method; Humans; Indans; Minocycline; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Nerve Tissue Proteins; Neuroprotective Agents; Oxepins; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Riluzole; Selegiline; Ubiquinone

2004
Monoamine oxidase B inhibitors for early Parkinson's disease.
    The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3

    Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Picolinic Acids; Randomized Controlled Trials as Topic; Selegiline

2005
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
    Scientific reports, 2017, 04-04, Volume: 8

    Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes

2017

Trials

2 trial(s) available for lazabemide and selegiline

ArticleYear
Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.
    European journal of clinical pharmacology, 1991, Volume: 40, Issue:2

    Topics: Aged; Blood Platelets; Brain; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Picolinic Acids; Selegiline; Tomography, Emission-Computed

1991
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide.
    Clinical neuropharmacology, 1993, Volume: 16, Issue:4

    Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Picolinic Acids; Selegiline

1993

Other Studies

22 other study(ies) available for lazabemide and selegiline

ArticleYear
Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives.
    Journal of medicinal chemistry, 1995, Nov-24, Volume: 38, Issue:24

    Topics: Animals; Brain; Female; Male; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrazoles

1995
Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
    Bioorganic & medicinal chemistry letters, 2005, Oct-15, Volume: 15, Issue:20

    Topics: Crystallography, X-Ray; Kinetics; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors

2005
Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues.
    Bioorganic & medicinal chemistry, 2012, Dec-15, Volume: 20, Issue:24

    Topics: Caffeine; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Structure-Activity Relationship

2012
Inhibition of monoamine oxidase by phthalide analogues.
    Bioorganic & medicinal chemistry letters, 2013, Mar-01, Volume: 23, Issue:5

    Topics: Benzofurans; Binding Sites; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Structure-Activity Relationship

2013
Inhibition of monoamine oxidase by 3,4-dihydro-2(1H)-quinolinone derivatives.
    Bioorganic & medicinal chemistry letters, 2013, Oct-15, Volume: 23, Issue:20

    Topics: Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Quinolones; Recombinant Proteins; Structure-Activity Relationship

2013
α-Tetralone derivatives as inhibitors of monoamine oxidase.
    Bioorganic & medicinal chemistry letters, 2014, Jun-15, Volume: 24, Issue:12

    Topics: Enzyme Activation; Humans; Models, Molecular; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Tetralones

2014
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
    Bioorganic & medicinal chemistry, 2015, Feb-15, Volume: 23, Issue:4

    Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics

2015
The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase.
    Bioorganic & medicinal chemistry letters, 2015, May-01, Volume: 25, Issue:9

    Topics: Benzodioxoles; Dioxanes; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phenols; Structure-Activity Relationship

2015
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
    Bioorganic & medicinal chemistry letters, 2015, Nov-15, Volume: 25, Issue:22

    Topics: Antiparkinson Agents; Chalcones; HeLa Cells; Humans; Hydrocarbons, Fluorinated; Kinetics; Kynuramine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyrroles; Structure-Activity Relationship; Thiophenes

2015
Inhibition of monoamine oxidase by benzoxathiolone analogues.
    Bioorganic & medicinal chemistry letters, 2016, Feb-15, Volume: 26, Issue:4

    Topics: Benzoxazoles; Humans; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Isoforms; Structure-Activity Relationship

2016
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
    European journal of medicinal chemistry, 2017, Jul-28, Volume: 135

    Topics: Benzoquinones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship

2017
Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors.
    Bioorganic & medicinal chemistry, 2018, 11-01, Volume: 26, Issue:20

    Topics: Chemistry Techniques, Synthetic; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Quinazolinones; Structure-Activity Relationship

2018
1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B.
    Bioorganic & medicinal chemistry letters, 2019, 11-01, Volume: 29, Issue:21

    Topics: Amino Acid Sequence; Antidepressive Agents; Benzenesulfonamides; Benzoates; Binding Sites; Drug Evaluation, Preclinical; Humans; Isomerism; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxadiazoles; Protein Binding; Protein Conformation; Structure-Activity Relationship; Sulfonamides; Zonisamide

2019
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
    Journal of medicinal chemistry, 2021, 02-25, Volume: 64, Issue:4

    Topics: Animals; Antidepressive Agents; Depression; Hep G2 Cells; Humans; Hydrazones; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Pyrazoles; Structure-Activity Relationship

2021
Measurement of cerebral monoamine oxidase B activity using L-[11C]deprenyl and dynamic positron emission tomography.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 1991, Volume: 11, Issue:4

    Topics: Aged; Brain; Female; Humans; Kinetics; Male; Middle Aged; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Picolinic Acids; Selegiline; Tomography, Emission-Computed

1991
Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
    Advances in neurology, 1990, Volume: 53

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dose-Response Relationship, Drug; Humans; Isoenzymes; Liver; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Picolinic Acids; Rats; Selegiline

1990
Reversible, enzyme-activated monoamine oxidase inhibitors: new advances.
    Pharmacological research communications, 1988, Volume: 20 Suppl 4

    Topics: Animals; Benzamides; Brain; Clorgyline; Humans; In Vitro Techniques; Male; Moclobemide; Monoamine Oxidase Inhibitors; Phenelzine; Picolinic Acids; Piperidines; Rats; Selegiline

1988
In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Biochemical pharmacology, 1995, Jun-29, Volume: 50, Issue:1

    Topics: Animals; Benzamides; Biogenic Monoamines; Blood Platelets; Male; Monoamine Oxidase Inhibitors; Picolinic Acids; Rats; Rats, Sprague-Dawley; Selegiline; Serotonin; Synaptosomes

1995
L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
    Journal of neurochemistry, 1994, Volume: 63, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Levodopa; Male; Monoamine Oxidase Inhibitors; Nerve Endings; Oxidopamine; Picolinic Acids; Rats; Rats, Sprague-Dawley; Selegiline

1994
Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
    Neurology, 1993, Volume: 43, Issue:10

    Topics: Aged; Antiparkinson Agents; Brain; Carbon Radioisotopes; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Picolinic Acids; Reference Values; Selegiline; Tomography, Emission-Computed

1993
Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.
    Biochemical pharmacology, 2000, Sep-01, Volume: 60, Issue:5

    Topics: Animals; Antioxidants; Dose-Response Relationship, Drug; Humans; Lipid Bilayers; Lipid Peroxidation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Picolinic Acids; Selegiline; Swine; Vitamin E; X-Ray Diffraction

2000
MAO-B inhibition by a single dose of l-deprenyl or lazabemide does not prevent neuronal damage following focal cerebral ischaemia in rats.
    Pharmacology & toxicology, 2000, Volume: 87, Issue:5

    Topics: Animals; Brain; Brain Ischemia; Cerebral Infarction; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Picolinic Acids; Rats; Rats, Wistar; Selegiline

2000